---
title: "Extending the Hierarchical Model for Antibody Kinetics"
author: "Kwan Ho Lee"
institute: "UC Davis"
date: today
format: 
  html: default
  beamer:
    theme: Madrid
    slide-level: 2
    keep-tex: true
    toc: false
    incremental: false
engine: knitr
---

## Overview

- Incorporates feedback from Dr. Morrison and Dr.Aiemjoy
- Focus exclusively on Teunis et al. (2016) model
- Clarifies model dynamics: growth, clearance, decay
- Uses updated parameter notation: $\mu_y$, $\mu_b$, $\gamma$, $\alpha$, $\rho$
- Assumes block-diagonal covariance structure across biomarkers

## Full Model Structure

**Two-phase within-host antibody kinetics:**

$$
\frac{dy}{dt} = 
\begin{cases}
\mu_1 b(t), & t < t_1 \\
- \alpha y(t)^r, & t \ge t_1
\end{cases}
\quad \text{with } 
\frac{db}{dt} = \mu_0 b(t) - c y(t) b(t)
$$

**Initial conditions:** $y(0) = y_0$, $b(0) = b_0$  
**Key transition:** $t_1$ is the time when $b(t_1) = 0$  
**Derived quantity:** $y_1 = y(t_1)$

## Definition of Model Quantities

**Parameters used in the dynamic model:**

- $\mu_0$: Pathogen growth rate  
- $\mu_1$: Antibody production rate (driven by pathogen)  
- $c$: Clearance rate — how effectively antibodies eliminate pathogen  
- $\alpha$: Antibody decay rate (governs speed of waning)  
- $r$: Shape of antibody decay (nonlinear power)  
- $y_0$: Initial antibody concentration at $t = 0$  
- $b_0$: Initial pathogen concentration at $t = 0$  
- $y_1 = y(t_1)$: Peak antibody level — computed at time of pathogen clearance  

**Note:** Only the first 7 are estimated. $y_1$ is derived from the ODE solution.

## Model Comparison: 2016 vs Our Formulation

| **Component** | **Teunis (2016)** | **Our Model** |
|--------------|-------------------|---------------|
| Pathogen ODE | $\mu_0 b(t) - c y(t)$ | $\mu_0 b(t) - c y(t) b(t)$ |
| Antibody ODE (pre-$t_1$) | $\mu y(t)$ | $\mu_1 b(t)$ |
| Antibody ODE (post-$t_1$) | $-\alpha y(t)^r$ | Same |
| Antibody growth type | Exponential | Pathogen-driven |
| Antibody rate name | $\mu$ | $\mu_1$ |
| $t_1$ formula | Uses $\mu$ | Uses $\mu_1$ |

**Note:**

- Antibody production depends on pathogen presence ($b(t)$), not constant exponential growth  
- Pathogen clearance is proportional to both antibody and pathogen levels ($c\,y(t)\,b(t)$)

## Hierarchical Priors – Subject-Level and Means

**Subject-level parameters:**

$$
\boldsymbol{\theta}_{ij} 
\sim 
\mathcal{N}(\boldsymbol{\mu}_j,\,\Sigma_j),\quad
\boldsymbol{\theta}_{ij} = 
\begin{bmatrix}
y_{0,ij} \\
b_{0,ij} \\
\mu_{0,ij} \\
\mu_{1,ij} \\
c_{ij} \\
\alpha_{ij} \\
r_{ij}
\end{bmatrix}
$$

**Hyperparameters – Means:**

- $\boldsymbol{\mu}_j$: population-level mean vector for biomarker $j$  
- Prior on $\boldsymbol{\mu}_j$:

$$
\boldsymbol{\mu}_j \sim \mathcal{N}(\boldsymbol{\mu}_{\mathrm{hyp},j},\,\Omega_{\mathrm{hyp},j})
$$

- $\boldsymbol{\mu}_{\mathrm{hyp},j}$ and $\Omega_{\mathrm{hyp},j}$ are fixed or weakly informative

## Clarifying Parameter Roles

**Why the confusion about number of parameters?**

- The dynamic model contains 8 named parameters:

$$
\mu_0, \mu_1, c, \alpha, r, y_0, b_0, y_1
$$

- But only 7 are estimated — the 8th ($y_1$) is computed.
- Let’s break this down carefully.

## Classification of Parameters

**Estimated Parameters (7 total):**

- **Core model parameters (5):**

$$
\mu_0,\ \mu_1,\ c,\ \alpha,\ r
$$

- **Initial conditions (2):**

$$
y_0,\ b_0
$$

**Derived Quantity (not estimated):**

- $y_1$: peak antibody level computed as $y(t_1)$

## Time of Pathogen Clearance: $t_1$

**Definition:** $t_1$ is the time at which the pathogen is cleared, i.e., $b(t_1) = 0$

**Analytic expression (Teunis et al., 2016):**

$$
t_1 = \frac{1}{\mu_1 - \mu_0} \log\left(1 + \frac{(\mu_1 - \mu_0)\,b_0}{c\,y_0} \right)
$$

**Key observations:**

- $t_1$ depends on $\mu_0$, $\mu_1$, $b_0$, $y_0$, and $c$
- Used to determine $y_1 = y(t_1)$ by solving the antibody ODE up to this point
- Not treated as an estimated parameter — it is computed from model inputs

## Why It’s a Seven-Parameter Model

- Our model estimates 7 parameters:
  - **5 core biological parameters:** $\mu_0,\ \mu_1,\ c,\ \alpha,\ r$
  - **2 initial conditions:** $y_0,\ b_0$
- But we often talk about an eighth quantity, $y_1$, the highest level of antibody.
- So why isn’t $y_1$ counted as a parameter?

## Why $y_1$ Is Not Fit Directly

- $y_1$ is the antibody level at the time the pathogen is cleared:

$$
y_1 = y(t_1) \quad \text{where } b(t_1) = 0
$$

- It is not an “input” to the model — we don’t estimate it with MCMC.
- Instead, we **calculate it from the model**:
  - We estimate parameters like $\mu_1$, $y_0$, $b_0$...
  - Then we solve the ODEs to find $t_1$ and compute $y(t_1)$
- In other words: $y_1$ is a **derived output**, not a parameter being fit.

## How $y_1$ Is Computed

- $y_1$ is computed by solving the coupled ODE system:

$$
\frac{dy}{dt} = \mu_1 b(t), \quad \frac{db}{dt} = \mu_0 b(t) - c y(t) b(t)
$$

- The solution is evaluated at $t = t_1$ (pathogen clearance point).
- Therefore:

$$
y_1 = y(t_1;\ \mu_1,\ y_0,\ b_0,\ \mu_0,\ c)
$$

## Recap: What We Estimate

**Seven model parameters:**

- $\mu_0,\ \mu_1,\ c,\ \alpha,\ r$ (biological process)
- $y_0,\ b_0$ (initial state)

**Derived quantity:**

- $y_1 = y(t_1)$, not directly estimated

## Hierarchical Bayesian Structure

**Individual parameters:**

$$
\theta_{ij} = \begin{bmatrix}
y_{0,ij} \\
b_{0,ij} \\
\mu_{0,ij} \\
\mu_{1,ij} \\
c_{ij} \\
\alpha_{ij} \\
r_{ij}
\end{bmatrix} 
\sim \mathcal{N}(\mu_j, \Sigma_j)
$$

**Hyperparameters:**

- $\mu_j$: population-level means (per biomarker $j$)
- $\Sigma_j$: $7 \times 7$ covariance matrix over parameters

## Subject-Level Parameters: $\boldsymbol{\theta}_{ij}$

$$
\boldsymbol{\theta}_{ij} \sim \mathcal{N}(\boldsymbol{\mu}_j,\,\Sigma_j),
\quad \boldsymbol{\theta}_{ij} \in \mathbb{R}^7
$$

**Where:**

$$
\boldsymbol{\theta}_{ij} = 
\begin{bmatrix}
y_{0,ij} \\
b_{0,ij} \\
\mu_{0,ij} \\
\mu_{1,ij} \\
c_{ij} \\
\alpha_{ij} \\
r_{ij}
\end{bmatrix},
\quad \Sigma_j \in \mathbb{R}^{7 \times 7}
$$

Each subject $i$ has a unique 7-parameter vector per biomarker $j$, capturing individual-level variation in dynamics.


## Hyperparameters: Priors on Population Means

**Population-level means:**

$$
\boldsymbol{\mu}_j \sim \mathcal{N}(\boldsymbol{\mu}_{\mathrm{hyp},j}, \Omega_{\mathrm{hyp},j})
$$

**Interpretation:**

- $\boldsymbol{\mu}_j$: average parameter vector for biomarker $j$
- $\boldsymbol{\mu}_{\mathrm{hyp},j}$: prior guess (e.g., vector of zeros)
- $\Omega_{\mathrm{hyp},j}$: covariance matrix encoding uncertainty

**Example:**

$$
\boldsymbol{\mu}_{\mathrm{hyp},j} = 0, \quad \Omega_{\mathrm{hyp},j} = 100 \cdot I_7
$$

---

## Hyperparameters: Priors on Covariance

**Covariance across parameters:**

$$
\Sigma_j^{-1} \sim \mathcal{W}(\Omega_j, \nu_j)
$$

- $\Sigma_j$: variability/covariance in subject-level parameters
- $\Omega_j$: prior scale matrix
- $\nu_j$: degrees of freedom

**Example:**

$$
\Omega_j = 0.1 \cdot I_7, \quad \nu_j = 8
$$

---

## Measurement Error and Precision Priors

**Observed antibody levels:**

$$
\log(y_{\text{obs},ij}) \sim \mathcal{N}(\log(y_{\text{pred},ij}), \tau_j^{-1})
$$

**Precision prior:**

$$
\tau_j \sim \text{Gamma}(a_j, b_j)
$$

- $\tau_j$: shared measurement precision for biomarker $j$
- Gamma prior allows flexible noise modeling

---

## Matrix Algebra Computation

Let $K = 7$ (parameters), $J$ biomarkers. Then:

$$
\Theta_i =
\begin{bmatrix}
\theta_{i1} & \theta_{i2} & \cdots & \theta_{iJ}
\end{bmatrix}
\in \mathbb{R}^{K \times J}
$$

Assume:

$$
\text{vec}(\Theta_i) \sim \mathcal{N}(\text{vec}(M), \Sigma_K \otimes I_J)
$$

---

## Matrix Algebra – Simplified Structure

Setup: $\Theta_i \in \mathbb{R}^{7 \times J}$

Model:

$$
\text{vec}(\Theta_i) \sim \mathcal{N}(\text{vec}(M), \Sigma_K \otimes I_J)
$$

- $\Sigma_K$: 7×7 covariance (same across biomarkers)
- $I_J$: biomarkers assumed uncorrelated
- Block-diagonal covariance

---

## Understanding $\text{vec}(\Theta_i)$

Each $\theta_{ij} \in \mathbb{R}^7$:

$$
\theta_{ij} =
\begin{bmatrix}
y_0 \\
b_0 \\
\mu_0 \\
\mu_1 \\
c \\
\alpha \\
r
\end{bmatrix}
$$

Flattening:

$$
\text{vec}(\Theta_i) \in \mathbb{R}^{7J \times 1}
$$

---

## Understanding $\text{vec}(M)$

Let $M = [\mu_1\, \mu_2\, \cdots\, \mu_J] \in \mathbb{R}^{7 \times J}$

Example for $J=3$:

$$
M =
\begin{bmatrix}
\mu_{1,1} & \mu_{1,2} & \mu_{1,3} \\
\mu_{2,1} & \mu_{2,2} & \mu_{2,3} \\
\mu_{3,1} & \mu_{3,2} & \mu_{3,3} \\
\mu_{4,1} & \mu_{4,2} & \mu_{4,3} \\
\mu_{5,1} & \mu_{5,2} & \mu_{5,3} \\
\mu_{6,1} & \mu_{6,2} & \mu_{6,3} \\
\mu_{7,1} & \mu_{7,2} & \mu_{7,3}
\end{bmatrix}
$$

---

## Covariance Structure: $\Sigma_K \otimes I_J$

$$
\text{Cov}(\text{vec}(\Theta_i)) = \Sigma_K \otimes I_J
$$

- $\Sigma_K$: parameter covariance matrix
- $I_J$: biomarker-wise independence
- Kronecker product yields block-diagonal matrix

---

## Example: Kronecker Product with $K=2$, $J=3$

Let:

$$
\Sigma_K =
\begin{bmatrix}
\sigma_{11} & \sigma_{12} \\
\sigma_{21} & \sigma_{22}
\end{bmatrix},\quad
I_3 =
\begin{bmatrix}
1 & 0 & 0 \\
0 & 1 & 0 \\
0 & 0 & 1
\end{bmatrix}
$$

Then:

$$
\Sigma_K \otimes I_3 \in \mathbb{R}^{6 \times 6}
$$

---

## Expanded Matrix: $\Sigma_K \otimes I_3$

$$
\Sigma_K \otimes I_3 =
\begin{bmatrix}
\sigma_{11} & 0 & 0 & \sigma_{12} & 0 & 0 \\
0 & \sigma_{11} & 0 & 0 & \sigma_{12} & 0 \\
0 & 0 & \sigma_{11} & 0 & 0 & \sigma_{12} \\
\sigma_{21} & 0 & 0 & \sigma_{22} & 0 & 0 \\
0 & \sigma_{21} & 0 & 0 & \sigma_{22} & 0 \\
0 & 0 & \sigma_{21} & 0 & 0 & \sigma_{22}
\end{bmatrix}
$$

---

## Next Steps: Modeling Correlation Across Biomarkers

Current Limitation:

- Biomarkers assumed independent: $I_J$

Planned Extension:

- Use full covariance $\Sigma_J$:

$$
\text{Cov}(\text{vec}(\Theta_i)) = \Sigma_K \otimes \Sigma_J
$$

---

## Extending to Correlated Biomarkers

Assume $K=3$, $J=3$

Define:

$$
\Sigma_K =
\begin{bmatrix}
\sigma_{11} & \sigma_{12} & \sigma_{13} \\
\sigma_{21} & \sigma_{22} & \sigma_{23} \\
\sigma_{31} & \sigma_{32} & \sigma_{33}
\end{bmatrix},\quad
\Sigma_J =
\begin{bmatrix}
\tau_{11} & \tau_{12} & \tau_{13} \\
\tau_{21} & \tau_{22} & \tau_{23} \\
\tau_{31} & \tau_{32} & \tau_{33}
\end{bmatrix}
$$

---

## Kronecker Product Structure: $\Sigma_K \otimes \Sigma_J$

$$
\Sigma_K \otimes \Sigma_J =
\begin{bmatrix}
\sigma_{11}\Sigma_J & \sigma_{12}\Sigma_J & \sigma_{13}\Sigma_J \\
\sigma_{21}\Sigma_J & \sigma_{22}\Sigma_J & \sigma_{23}\Sigma_J \\
\sigma_{31}\Sigma_J & \sigma_{32}\Sigma_J & \sigma_{33}\Sigma_J
\end{bmatrix}
$$

Now biomarkers and parameters can be correlated.

---

## Expanded Form: $\Sigma_K \otimes \Sigma_J$ (3x3)

The $9 \times 9$ matrix contains all combinations $\sigma_{ab}\tau_{cd}$

Not block-diagonal — includes cross-biomarker correlation

---

## Practical To-Do List (for Chapter 2)

**Model Implementation:**

- Define full $\Sigma_J$ and prior: $\Sigma_J^{-1} \sim \mathcal{W}(\Psi, \nu)$  
- Implement $\Sigma_K \otimes \Sigma_J$ in JAGS

**Simulation + Validation:**

- Simulate individuals with correlated biomarkers  
- Fit both block-diagonal and full-covariance models  
- Compare fit: DIC, WAIC, predictive checks

